BDSI - BioDelivery Sciences International, Inc.
| Previous Close | 3.5900 |
| Open | 3.6700 |
| Bid | 3.63 x 800 |
| Ask | 3.64 x 1800 |
| Day's Range | 3.6300 - 3.6700 |
| 52 Week Range | 1.7000 - 4.1400 |
| Volume | 133,191 |
| Avg. Volume | 619,865 |
| Market Cap | 257.317M |
| Beta (3Y Monthly) | -1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.94 |
| Earnings Date | Nov 7, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.20 |
- GlobeNewswire•2 hours ago
Avadel Pharmaceuticals Appoints Kevin Kotler to the Company’s Board of Directors
Avadel Pharmaceuticals plc (AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced that Kevin Kotler, the founder and Portfolio Manager of Broadfin Capital, LLC, has been appointed to the Company’s Board of Directors and will immediately join the Board. The Company also intends to nominate and appoint an additional director, in consultation with Broadfin, in the very near future.
- Zacks•3 days ago
BioDelivery (BDSI) Down 1.6% Since Last Earnings Report: Can It Rebound?
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Thomson Reuters StreetEvents•21 days ago
Edited Transcript of BDSI earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 BioDelivery Sciences International Inc Earnings Call
- Zacks•29 days ago
BioDelivery (BDSI) Q3 Earnings Beat, Sales In Line, Stock Up
BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q3. Sales were almost in line with the consensus mark.
- GlobeNewswire•29 days ago
Consolidated Research: 2018 Summary Expectations for Murphy Oil, REGENXBIO, CRA International,Inc, Carriage Services, CONMED, and BioDelivery Sciences International — Fundamental Analysis, Key Performance Indications
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•last month
BioDelivery Sciences International (BDSI) Reports Q3 Loss, Misses Revenue Estimates
BioDelivery (BDSI) delivered earnings and revenue surprises of 28.57% and -0.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
BioDelivery: 3Q Earnings Snapshot
The Raleigh, North Carolina-based company said it had a loss of 29 cents per share. Losses, adjusted for non-recurring costs, came to 10 cents per share. The results topped Wall Street expectations. The ...
- GlobeNewswire•last month
BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results
BELBUCA® continued on an accelerated growth trajectory, with revenue increasing 92% YOY and 27% versus prior quarterBELBUCA total prescriptions experienced its largest quarter.
- American City Business Journals•last month
The most valuable public companies in the Triangle (Slideshow)
The number of public companies based in the Triangle has shrunk in recent years as acquisitions have meant a change in headquarters location, or even taking the company private.
- Zacks•last month
5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings
There are still a number of drug/biotech companies poised to surpass third-quarter estimates.
- GlobeNewswire•last month
BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA®
More than 100 million Covered Lives Now Have Preferred Access to BELBUCA RALEIGH, N.C., Nov. 01, 2018 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly.
- Zacks•last month
BioDelivery Sciences International (BDSI) Expected to Beat Earnings Estimates: Should You Buy?
BioDelivery (BDSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Investopedia•last month
Penny Stocks to Buy Using Technical Analysis for November 2018
Penny stocks got battered and bruised during the month of October, undermined by a broad-based retreat that dropped the Russell 2000 small-cap index to an eight-month low. The broad market could post new lows in early November, but a profitable relief rally should unfold in coming weeks, favoring dip trades on penny stocks that have held technical support levels through the maelstrom. This month's penny stock list includes several of these plays, but it's important to think and act defensively, placing stop losses immediately after entry. Penny Stock Picks to Buy Using Technical Analysis for November 1.
- GlobeNewswire•last month
BioDelivery Sciences Announces Changes to its Executive Leadership Team
James Vollins joins the Company in role of General Counsel, Chief Compliance Officer, and Corporate Secretary Ernest De Paolantonio, Chief Financial Officer announces plan to.
- GlobeNewswire•2 months ago
New Research: Key Drivers of Growth for IDT, Live Nation Entertainment, BioDelivery Sciences International, Spero Therapeutics, Aimmune Therapeutics, and Cars — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•2 months ago
Can The Uptrend Continue for BioDelivery Sciences International (BDSI)?
Investors certainly have to be happy with BioDelivery Sciences International, Inc. (BDSI) and its short term performance.
- American City Business Journals•2 months ago
From Iqvia's Bousbib to Red Hat's Whitehurst: Who made the most from inside stock sales in 3Q2018
From Iqvia to Red Hat to Bandwidth, insiders at Triangle companies continued to rake in millions in the third quarter by selling shares, U.S. Securities and Exchange Commission filings show.
- Simply Wall St.•2 months ago
Who Are The Major Shareholders Of BioDelivery Sciences International Inc (NASDAQ:BDSI)?
The big shareholder groups in BioDelivery Sciences International Inc (NASDAQ:BDSI) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...
- GlobeNewswire•3 months ago
BioDelivery Sciences to Host Institutional Investor and Analyst Day on Friday, October 5, 2018
RALEIGH, N.C., Sept. 13, 2018-- BioDelivery Sciences International, Inc., a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of BDSI earnings conference call or presentation 9-Aug-18 8:30pm GMT
Q2 2018 BioDelivery Sciences International Inc Earnings Call
